Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6448-6459

  Hu, Zheng ^a,b   Xia, Jinxing ^b   Fan, Wei ^a   Wargo, Jennifer ^c   Yang, Yong Guang ^a,b  

^a JILIN UNIVERSITY   (China)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Animal model; Immune response; Immunity; Immunology and microbiology section; Immunotherapy; Melanoma; T cells; TCR

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GRANZYME B; MELAN A; PEPTIDE VACCINE; PERFORIN; RAPAMYCIN; RECOMBINANT INTERLEUKIN 15; HLA A2 ANTIGEN; PEPTIDE FRAGMENT;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MELANOMA METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; ANIMAL; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; NONOBESE DIABETIC MOUSE; SCID MOUSE; SECONDARY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84964578397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7044     Document Type: Article

References (36)

1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research. 2011; 17:4550-4557.
2. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD and Dasanu CA. Immunotherapy for Melanoma: Current Status and Perspectives. Journal of Immunotherapy. 2010; 33:570-590 510.1097/CJI.1090b1013e3181e1032e1098.
3. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2013; 369:122-133.
4. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Science Translational Medicine. 2013; 5:200ra116.
5. Yang L, Qin XF, Baltimore D and Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:6204-6209.
6. Yang L and Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:4518-4523.
7. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z and Zack JA. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proceedings of the National Academy of Sciences. 2011; 108:E1408-E1416.
8. Lan P, Wang L, Diouf D, Eguchi H, Bronson R, Sachs DH, Sykes M and Yang YG. Induction of human T cell tolerance to porcine xenoantigens through mixed hematopoietic chimerism. Blood. 2004; 103:3964-3969.
9. Lan P, Tonomura N, Shimizu A, Wang S and Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006; 108:487-492 [Epub 2006 Jan 2012].
10. Tonomura N, Habiro K, Shimizu A, Sykes M and Yang YG. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood. 2008; 111:4293-4296.
11. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee C-CR, Restifo NP, Schwarz SL, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114:535-546.
12. Chen Q, Khoury M and Chen J. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proceedings of the National Academy of Sciences. 2009; 106:21783-21788.
13. Kalscheuer H, Danzl N, Onoe T, Faust T, Winchester R, Goland R, Greenberg E, Spitzer TR, Savage DG, Tahara H, Choi G, Yang Y-G and Sykes M. A model for personalized in vivo analysis of human immune responsiveness. Science Translational Medicine. 2012; 4:125ra130.
14. Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. NatRevCancer. 2008; 8:299-308.
15. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314:126-129.
16. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114:535-546.
17. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA and Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer research. 2006; 66:8878-8886.
18. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C and Greenberg PD. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007; 109:2331-2338.
19. Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen, JB et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature medicine. 2010; 16:565-570, 561p following 570.
20. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ and Rosenberg SA. MHC Class I-restricted Recognition of a Melanoma Antigen by a Human CD4+ Tumor Infiltrating Lymphocyte. Cancer research. 1999; 59:6230-6238.
21. Voelkl S, Moore T, Rehli M, Nishimura M, Mackensen A and Fischer K. Characterization of MHC class-I restricted TCRαβ+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother. 2009; 58:709-718.
22. Johnson LA, Heemskerk B, Powell DJ, Jr., Cohen CJ, Morgan RA, Dudley ME, Robbins PF and Rosenberg SA. Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. The Journal of Immunology. 2006; 177:6548-6559.
23. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA and Morgan RA. Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase. The Journal of Immunology. 2010; 184:5988-5998.
24. Xue S-A, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC and Stauss HJ. Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. OncoImmunology. 2013; 2:e22590.
25. Willemsen R, Ronteltap C, Heuveling M, Debets R and Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR [alpha][beta] gene transfer requires CD8[alpha]. Gene Ther. 2005; 12:140-146.
26. Soto C, Stone J, Chervin A, Engels B, Schreiber H, Roy E and Kranz D. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 2013; 62:359-369.
27. Steel JC, Waldmann TA and Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends in Pharmacological Sciences. 2012; 33:35-41.
28. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y and Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. The Journal of Clinical Investigation. 2005; 115:1177-1187.
29. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA and Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:1969-1974.
30. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP and Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460:108-112.
31. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang L-S, Jones RG and Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009; 460:103-107.
32. Rao Rajesh R, Li Q, Bupp Melanie RG and Shrikant Protul A. Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation. Immunity. 2012; 36:374-387.
33. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W and Shrikant PA. Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity. The Journal of Immunology. 2012; 188:3080-3087.
34. Thomas D, Doty R, Tosic V, Liu J, Kranz D, McFadden G, MacNeill A and Roy E. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother. 2011; 60:1461-1472.
35. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science. 2002; 298:850-854.
36. Riddell SR and Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. JImmunolMethods. 1990; 128:189-201.